Idarucizumab (Praxbind®) – studie RE-VERSE AD

• Title in English: Idarucizumab (Praxbind®) – the RE-VERSE AD study
• Authors: PENKA Miroslav; MICHALCOVÁ Jana; ZAVŘELOVÁ Jiřina; PRUDKOVÁ Marie; BULIKOVÁ Alena
• Year of publication: 2016
• Type: Article in Periodical
• Magazine / Source: Hypertenze & kardiovaskulární prevence
• MU Faculty or unit: Faculty of Medicine
• Field: Oncology and hematology
• Keywords: thrombin; inhibitor; antidote; idarucizumab; RE-VERSE AD
• Description: The recent introduction of idarucizumab as specific antidote for dabigatran to clinical practice represents an important progress in safety of antithrombotic therapy. The RE-VERSE AD study confirmed the efficacy and safety of idarucizumab for dabigatran reversal.